Thalidomide-O-amido-C6-NH2 (TFA) is primarily used in research and development, particularly in the field of targeted drug delivery and protein degradation. It serves as a key component in the design of PROTACs (Proteolysis Targeting Chimeras), which are bifunctional molecules aimed at degrading specific disease-causing proteins. This compound is often utilized to create conjugates that can selectively bind to target proteins and recruit E3 ubiquitin ligases, leading to the ubiquitination and subsequent degradation of the protein via the proteasome pathway. Its application is significant in studying cancer, neurodegenerative diseases, and other conditions where targeted protein degradation offers therapeutic potential. Additionally, it is employed in chemical biology to explore protein-protein interactions and cellular signaling pathways.